Gregg Gilbert
Stock Analyst at Truist Securities
(2.86)
# 1,250
Out of 4,479 analysts
42
Total ratings
51.11%
Success rate
5.29%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.36 | +49.65% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $32.04 | +15.48% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $40.45 | +107.66% | 4 | Sep 15, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $430 → $525 | $906.71 | -42.10% | 6 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $10.66 | +21.95% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $16.80 | - | 8 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $127.72 | - | 2 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | n/a | $9.30 | - | 1 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | n/a | $1.39 | - | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | n/a | $0.16 | - | 1 | Jan 24, 2020 | |
| PRGO Perrigo Company | Downgrades: Hold | n/a | $25.99 | - | 2 | Aug 10, 2018 | |
| ZTS Zoetis | Maintains: Hold | n/a | $174.81 | - | 4 | Feb 16, 2018 | |
| TEVA Teva Pharmaceutical | Maintains: Hold | n/a | $16.55 | - | 2 | Feb 9, 2018 | |
| LGND Ligand Pharmaceuticals | Downgrades: Sell | n/a | $84.79 | - | 3 | Nov 20, 2017 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | n/a | $105.09 | - | 2 | Aug 9, 2017 | |
| ABBV AbbVie | Maintains: Hold | n/a | $165.96 | - | 1 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.36
Upside: +49.65%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $32.04
Upside: +15.48%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $40.45
Upside: +107.66%
Eli Lilly
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $906.71
Upside: -42.10%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $10.66
Upside: +21.95%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $16.80
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: n/a
Current: $127.72
Upside: -
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: n/a
Current: $9.30
Upside: -
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: n/a
Current: $1.39
Upside: -
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: n/a
Current: $0.16
Upside: -
Perrigo Company
Aug 10, 2018
Downgrades: Hold
Price Target: n/a
Current: $25.99
Upside: -
Zoetis
Feb 16, 2018
Maintains: Hold
Price Target: n/a
Current: $174.81
Upside: -
Teva Pharmaceutical
Feb 9, 2018
Maintains: Hold
Price Target: n/a
Current: $16.55
Upside: -
Ligand Pharmaceuticals
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $84.79
Upside: -
Jazz Pharmaceuticals
Aug 9, 2017
Maintains: Buy
Price Target: n/a
Current: $105.09
Upside: -
AbbVie
Jul 17, 2017
Maintains: Hold
Price Target: n/a
Current: $165.96
Upside: -